TPX 100
Alternative Names: TPX-100Latest Information Update: 20 Oct 2021
At a glance
- Originator OrthoTrophix
- Class Antirheumatics; Glycoproteins
- Mechanism of Action Aggrecan stimulants; Collagen stimulants; Integrin stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Osteoarthritis
Most Recent Events
- 20 Oct 2021 Efficacy results of a clinical study demonstrating disease modification in knee osteoarthritis (OA) released by the company
- 12 May 2020 Efficacy data from a phase II TPX-100-5 trial in Osteoarthritis released by OrthoTrophix
- 02 Mar 2020 Updated efficacy data from the phase II TPX-100-1 trial in Osteoarthritis released by OrthoTrophix